Fig. 1From: Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectivelyTimeline of the case 1’s disease from diagnosis to death (A). Chest computed tomography (CT) scans at diagnosis (B), and after 2 cycles of Cisplatin + Paclitaxel (C), subsequent chest CT scans performed 1 month (D), 2 months (E) and 3 months (F) after initiation of crizotinib treatmentBack to article page